摘要
目的:分析塞来昔布联合甲钴胺对腰椎间盘突出症患者镇痛及腰椎功能影响。方法:选取2022年4月—2024年1月我院收治的82例腰椎间盘突出患者为研究对象。以随机数字表法分为观察组与对照组,各41例,对照组采用甲钴胺治疗,观察组采用甲钴胺+塞来昔布治疗。对比两组临床疗效、腰椎功能、血清炎性因子、疼痛程度。结果:观察组临床有效率为91.84%,高于对照组的73.47%(P<0.05);观察组治疗后、随访时JOA评分高于对照组,ODI评分低于对照组(P<0.05);观察组治疗后PRI、VAS及PPI评分低于对照组(P<0.05);观察组治疗后TNF-α、IL-6及IL-1水平低于对照组(P<0.05)。结论:对于腰椎间盘突出症患者,甲钴胺联合应用塞来昔布治疗可有效改善患者腰椎功能,并降低疼痛程度及血清炎症因子水平,有利于其恢复。
Objective:To analyze the effect of celecoxib combined with mecobalamin on analgesia and lumbar function in patients with lumbar disc herniation.Methods:A total of 82 patients with lumbar disc herniation admitted to our hospital from April 2022 to January 2024 were selected as the research objects.They were divided into observation group and control group by random number table method,with 41 patients in each group.The control group was treated with mecobalamin,and the observation group was treated with mecobalamin+celecoxib.The clinical efficacy,lumbar function,serum inflammatory factors and pain degree were compared between the two groups.Results:The clinical effective rate of the observation group was 91.84%,which was higher than 73.47%of the control group(P<0.05).After treatment and during follow-up,the JOA score of the observation group was higher than that of the control group,and the ODI score was lower than that of the control group(P<0.05).After treatment,the scores of PRI,VAS and PPI in the observation group were lower than those in the control group(P<0.05).After treatment,the levels of TNF-α,IL-6 and IL-1 in the observation group were lower than those in the control group(P<0.05).Conclusion:For patients with lumbar disc herniation,mecobalamin combined with celecoxib treatment can effectively improve the lumbar function of patients,and reduce the degree of pain and serum inflammatory factor levels,which is conducive to its recovery.
作者
齐德重
吴海洋
黄辉
QI Dezhong;WU Haiyang;HUANG Hui(Department of Orthopaedics,Shangqiu Central Hospital,Shangqiu 476000,Henan,China)
出处
《中国药物滥用防治杂志》
CAS
2024年第7期1295-1298,共4页
Chinese Journal of Drug Abuse Prevention and Treatment
基金
河南省医学科技攻关计划项目(编号:LHGJ20200933)。
